Literature DB >> 30286224

Immune Checkpoint Inhibitor Toxicity in 2018.

Douglas B Johnson1,2, Sunandana Chandra3,4, Jeffrey A Sosman3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30286224     DOI： 10.1001/jama.2018.13995

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  82 in total

1.  Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand.

Authors:  James Randall Patrinely; Arissa C Young; Henry Quach; Grant R Williams; Fei Ye; Run Fan; Leora Horn; Kathryn E Beckermann; Erin A Gillaspie; Jeffrey A Sosman; Debra L Friedman; Javid J Moslehi; Douglas B Johnson
Journal:  Eur J Cancer       Date:  2020-06-27       Impact factor: 9.162

2.  Demographic Factors Associated with Toxicity in Patients Treated with Anti-Programmed Cell Death-1 Therapy.

Authors:  Kaustav P Shah; Haocan Song; Fei Ye; Javid J Moslehi; Justin M Balko; Joe-Elie Salem; Douglas B Johnson
Journal:  Cancer Immunol Res       Date:  2020-04-29       Impact factor: 11.151

3.  Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 Therapy.

Authors:  Henry T Quach; Charles J Robbins; Justin M Balko; Charles Y Chiu; Steve Miller; Michael R Wilson; George E Nelson; Douglas B Johnson
Journal:  Oncologist       Date:  2019-04-01

Review 4.  Immunotherapy in Older Adults with Cancer.

Authors:  Richard Curtis Godby; Douglas B Johnson; Grant R Williams
Journal:  Curr Oncol Rep       Date:  2019-05-07       Impact factor: 5.075

Review 5.  Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease.

Authors:  Dominic P Del Re; Dulguun Amgalan; Andreas Linkermann; Qinghang Liu; Richard N Kitsis
Journal:  Physiol Rev       Date:  2019-10-01       Impact factor: 37.312

Review 6.  Prevention and Treatment of Chemotherapy-Induced Cardiotoxicity.

Authors:  Monica Samuel Avila; Suellen Rodrigues Rangel Siqueira; Silvia Moreira Ayub Ferreira; Edimar Alcides Bocchi
Journal:  Methodist Debakey Cardiovasc J       Date:  2019 Oct-Dec

Review 7.  [Novel cancer treatment and the cardiovascular risk : What should cardiologists know?]

Authors:  Matthias Totzeck; Tienush Rassaf
Journal:  Herz       Date:  2020-04       Impact factor: 1.443

8.  Association of Anti-Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma.

Authors:  Henry T Quach; Anna K Dewan; Elizabeth J Davis; Kristin K Ancell; Run Fan; Fei Ye; Douglas B Johnson
Journal:  JAMA Oncol       Date:  2019-06-01       Impact factor: 31.777

9.  Anti-PD-1-Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients.

Authors:  Douglas B Johnson; Kevin B Taylor; Justine V Cohen; Noura Ayoubi; Alexandra M Haugh; Daniel Y Wang; Brian D Schlick; Amber L Voorhees; Kenneth L Gage; Florian J Fintelmann; Ryan J Sullivan; Zeynep Eroglu; Richard G Abramson
Journal:  Cancer Immunol Res       Date:  2019-08-28       Impact factor: 11.151

Review 10.  Cardiovascular toxicities associated with immune checkpoint inhibitors.

Authors:  Jiun-Ruey Hu; Roberta Florido; Evan J Lipson; Jarushka Naidoo; Reza Ardehali; Carlo G Tocchetti; Alexander R Lyon; Robert F Padera; Douglas B Johnson; Javid Moslehi
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.